Suppression of synthesis and utilization of tropomyosin in mouse and rat fibroblasts by transforming growth factor alpha: a pathway in oncogene action.
Two events which commonly occur during transformation of murine and avian fibroblasts by retroviral oncogenes are production of transforming growth factor alpha (TGF-alpha) and suppression of tropomyosin synthesis. TGF has been proposed as a mediator of transformation through autocrine stimulation. Suppression of tropomyosin synthesis may contribute to the transformed phenotype through destabilization of actin microfilaments and cytoskeletal derangement. To determine whether suppression of tropomyosin synthesis might be a consequence of the action of TGF-alpha we studied tropomyosin synthesis in rat (normal rat kidney) and mouse (NIH3T3) fibroblasts treated with TGF-alpha. In a serum-containing system, addition of TGF-alpha or epidermal growth factor to normal rat kidney monolayers in subnanomolar concentrations induced morphological changes consistent with transformation. These changes were accompanied by prominent suppression of synthesis of Mr 36,000 and 39,000 tropomyosins. Similar suppression was observed in NIH3T3 cells. Inhibition of tropomyosin synthesis began almost immediately after addition of TGF-alpha and became progressively more pronounced during the succeeding 48 h. Suppression of tropomyosin synthesis was correlated with reduced expression of 1.1- and 1.8-kilobase tropomyosin mRNAs in both TGF-treated normal rat kidney cells and v-Ki-ras-transformed NIH3T3 cells. Rapid onset of a specific block in utilization of newly synthesized tropomyosin for formation of cytoskeletal elements was also demonstrated following TGF-alpha treatment. The evidence suggests that this block may be a specific effect of TGF-alpha treatment and that reduced expression of tropomyosin gene products may be either an independent event or a regulatory consequence of the block to utilization. The data support the conclusion that suppression of tropomyosin synthesis in cells transformed by a number of retroviral oncogenes results from the autocrine action of TGF-alpha.
D000818:Animals; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology; D066246:ErbB Receptors / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008970:Molecular Weight; D009857:Oncogenes; D010455:Peptides / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D013997:Time Factors; D015291:Transforming Growth Factors; D014335:Tropomyosin / Q000096:biosynthesis* / Q000378:metabolism
D010455:Peptides; D012333:RNA, Messenger; D014335:Tropomyosin; D004815:Epidermal Growth Factor; D015291:Transforming Growth Factors; D066246:ErbB Receptors